Skip to main content
Signal8

Seaport Therapeutics, Inc. (SPTX)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Seaport Therapeutics, Inc. Common Stock logo

Seaport Therapeutics, Inc. Common Stock

NASDAQ:SPTXHealthcare
+0.53%$21.61
Mkt Cap$1.16B
Float19.35M
O/S53.53M
VOL87K sh
$ Vol$1.9M
RVOL0.37×
Inst Own70.3%
SI19.2%
Dilution
Seaport Therapeutics, Inc. Common Stock logoNASDAQ:SPTX$21.61+0.53%
Historical Data
DateOpenHighLowCloseVolume
Nov 9, 202621.8922.2621.2721.5486,939
Nov 6, 202620.8521.7519.7721.50227,030
Nov 5, 202621.0721.0719.8820.39221,061
Nov 4, 202621.6121.7620.0220.96336,175
Nov 3, 202620.0120.5619.5120.20393,650
Nov 2, 202619.6821.0719.1320.01527,903
Oct 30, 202620.9621.1619.0019.60549,190
Oct 29, 202620.7122.0920.4821.10272,148
Oct 28, 202620.8121.0219.5220.38355,272
Oct 27, 202621.0022.0520.7321.28219,356
Oct 26, 202620.7621.6920.3420.83124,687
Oct 23, 202620.7220.8919.9920.61164,567
Oct 22, 202619.7421.0719.7420.76131,422
Oct 21, 202619.2720.1318.0019.73134,584
Oct 20, 202617.9819.6317.5619.28145,273
Oct 19, 202617.8318.1217.4717.79145,736
Oct 16, 202617.6318.0017.1417.83184,539
Oct 15, 202616.8217.8916.6117.60164,911
Oct 14, 202615.9816.9715.7916.68208,623
Oct 13, 202617.0817.6216.0316.08227,203
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$46.00+112.8%
Low $46High $46
Ratings Distribution
BUY
1
HOLD
0
SELL
0
TOTAL1
Insider Trades
InsiderTypeShares
Torres Denice profile photoTorres DenicePurchase5.0K
HOMBACH ROBERT J. profile photoHOMBACH ROBERT J.Purchase13.0K
Loebel Antony profile photoLoebel AntonyConversion of Derivative20.1K
PAUL STEVEN M profile photoPAUL STEVEN MConversion of Derivative210.5K
ARCH Venture Partners XII, LLC profile photoARCH Venture Partners XII, LLCConversion of Derivative2.51M
ARCH Venture Partners XII, LLC profile photoARCH Venture Partners XII, LLCConversion of Derivative2.68M
Shareholders
70.3%
Institutional
(59)
1.7%
Insiderⓘ
(5)
0.0%
5%+ Owners
(0)
27.9%
Unattributed (incl. retail)ⓘ
Institutional70.3%
Insider1.7%
Unattributed (incl. retail)27.9%
Sources: 13F, Form 4O/S: 53.5M · as of 27 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines.

The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines.

The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors.

The company was founded in 2024 and is based in Boston, Massachusetts.

Key Metrics
Market Cap$1.16B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership70.32%

based on 53.53M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateMay 1, 2026
Shares Outstanding53.53M
Authorized Shares
Float19.35M
52-Week Range
$14.85$23.00
$21.61(83rd percentile)
Volume
Average Daily Volume235.54K
86.94K today vs 235.54K avg(-63%)

30d Avg

235.54K

60d Avg

275.15K

90d Avg

229.71K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...